The number of COVID-19 vaccination doses administered per 100 people in France rose to 228 as of Oct 27 2023. This dataset includes a chart with historical data for France Coronavirus Vaccination Rate.

Disclaimer

All information presented here is for display purpose only, and may not be complete nor accurate. This information does not constitute a financial advice, and should not be used to make any investment decisions or financial transactions. This author rejects any claims for liabilities resulting from the use, misuse, or abuse of this information. Use at your own risk.

Context

This small dataset has been created in order to prove my mom it's important for the world to get as much people as we can vaccinated

Content

You will find a dataset made of 2 taken from the french website https://www.data.gouv.fr gathering a lot of datasets

Features

This document gathers both the vaccine data day by day and cumulated, and the COVID-19 best indicators to follow the evolution of the sanitary crisis.

Here are the features :

• extract_date : row date formatted dd/mm/yyyy

• tx_incid : The incidence rate corresponds to the number of people who tested positive (RT-PCR and antigen test) for the first time in more than 60 days compared to the size of the population. It is expressed per 100,000 inhabitants and makes it possible to compare geographic areas with one another.

• R : The virus reproduction number: this is the average number of people an infected person can infect. If the effective R is greater than 1, the epidemic develops; if it is less than 1, the epidemic recedes. This indicator, stopped on Tuesday and updated on Thursday, is an indicator of the epidemiological situation approximately 7 days previously and must be interpreted in the light of screening and data reporting activities. The indicator is updated once a week.

• taux occupation sae (%) : This indicator reflects the level of demand for resuscitation but also the level of stress on hospital resuscitation capacities. This is the proportion of patients with COVID-19 currently in intensive care, intensive care, or in a continuous monitoring unit compared to the total beds in initial capacity, that is to say before increasing the capacity. resuscitation beds in a hospital.

• tx_pos : The positivity rate corresponds to the number of people tested positive (RT-PCR and antigen test) for the first time in more than 60 days compared to the total number of people tested positive or negative over a given period; and who have never tested positive in the previous 60 days.

• n_dose1 : Number of 1rst dose of vaccine administered this day

• n_complet : Number of complete coverage granted this day (1 dose for J&J - 2 doses for Pfitzer/AstraZenecca/Moderna - 1 dose if you ever had COVID-19 before)

• n cum dose1 : Cumulated number of 1rst doses administered

• n cum complet : Cumulated number of complete coverages

Context

"Experts have warned that the race to produce a Covid-19 vaccine could make the pandemic worse in the long run. A weak or partially effective candidate could potentially result in people believing they are immune to the virus, resulting in higher rates of infection. That warning was recently voiced by Professor Richard Peto of Oxford University and an adviser to the World Health Organization, who said that the first vaccine would be distributed all over the world, even if it had low efficacy."

" Around the world, some publics are extremely cautious about a vaccine and remain reluctant to take one, with the vast majority of respondents citing potential side effects as a reason to avoid getting one."

"So where are people least concerned about taking a Covid-19 vaccine if it was available? Ipsos MORI found that 97 percent of people in China would take one, along with 88 percent in Brazil, 87 percent in India and 85 percent in the UK. Russia recently announcing that it was aiming to bring its Sputnik V vaccine to the market at some stage this month, despite the fact that it did not undergo large scale testing. Only 54 percent of Russians say they would take a vaccine if it was available, with the share of people in France also low at 59 percent. In both Germany and the United States, 67 percent of respondents say they would agree to take a vaccine, according to the research." https://www.statista.com/chart/22768/share-who-agree-they-would-take-a-covid-19-vaccine/

Content

This chart shows the share who agree/disagree they would take a Covid-19 vaccine if it was available. Source: Ipsos MORI

Acknowledgements

Source: Ipsos MORI Niall McCarthy, Data Journalist. https://www.statista.com/chart/22768/share-who-agree-they-would-take-a-covid-19-vaccine/

Photo by Markus Winkler on Unsplash

Inspiration

Covid-19.

Pneumococcal disease (PD) is associated with high morbidity and mortality, specifically among individuals ≥65 years of age and those with underlying medical conditions (UMCs). This retrospective cohort study estimated the clinical burden of PD in adults ≥18 years of age with or without UMCs in France. Data were obtained from the French National Health Data System for four yearly cohorts (1 January 2015–31 December 2018). Characteristics of patients with UMCs, with or without PD (UMC population), and the incidence rate and lethality rate of PD leading to hospitalization (in-patient PD population), stratified by age and risk status, were described. In the UMC population (n = 7,947,622; mean age: 65 years), the incidence rate of in-patient PD episodes was 121.98 per 100,000 person-years and was highest among individuals ≥65 years of age (138.52) and in those considered medium-risk (102.45) or high-risk (165.77). In the in-patient PD population (n = 41,885), 59.6% were ≥65 years of age; 1-year all-cause mortality following the initial in-patient PD episode was 26.5%. Individuals ≥65 years of age (regardless of risk status) had a higher risk of PD leading to hospitalization than individuals 18–64 years of age. This study shows a high burden of PD in France due to in-patient PD among adults with UMCs, particularly in those ≥65 years of age, despite their eligibility for pneumococcal vaccination. This highlights the need for higher vaccination coverage, supported by the recent extension of vaccination to all people ≥65 years of age, regardless of their health risk status.